Clinical Trials Logo
  1. Home
  2. Diabetes Mellitus, Type 2
  3. NCT02465411

Long Term CGM Treatment in Patients With Type 1 Diabetes Treated With Insulin Injections

Diabetes Mellitus Type 1 Clinical Trial

Official title:
Long-term Effects of Continuous Glucose Monitoring in Patients With Type 1 Diabetes Treated With Multiple Daily Insulin Injections - Extension of CGMMDI Trial

Clinical Trial Summary

A keystone in preventing diabetic complications in patients with type 1 diabetes is good glycaemic control. Frequent self-measurements of blood glucose (SMBG) levels have been an essential part of insulin dosing before meals. However, in recent years continuous glucose monitoring (CGM) has become a treatment option to inform the patient when glucose levels may be too high or low.

In some countries, including Sweden, CGM is reimbursed only when combined with continuous subcutaneous insulin infusions (CSII) in patients with very poor glycaemic control or a history of repeated severe hypoglycaemia in adults with type 1 diabetes. This is based on existing clinical trial data showing a beneficial effect on HbA1c when CGM is combined with CSII. However, despite the fact that the majority of adults with type 1 diabetes are treated with multiple daily insulin injections (MDI), studies on the effect of CGM in patients with type 1 diabetes treated with MDI are sparse. Therefore, the investigators initiated the CGMMDI trial, an ongoing, cross-over clinical trial including 161 MDI patients receiving CGM over 6 months, followed by conventional therapy over six months, with a four-month wash-out period in-between treatment. Evaluations include glycaemic control, hypoglycaemia, quality of life, fear of hypoglycaemia, treatment satisfaction, physical activity, and safety.

From a research or regulatory standpoint, long-term data on treatment effects are expected to a greater extent today than in previous years, due to various reasons, e.g., to evaluate any sustained beneficial effects over time, or long-term patient safety. Accordingly, follow-up of treatment in an extension phase after randomized diabetes trials have become more common over time, especially where many novel glucose-lowering treatments are concerned. Therefore, the aim of the current study is to evaluate long-term effects of CGM in patients with type 1 diabetes treated with MDI. Patients who consent in an extension phase over 1 year of the CGMMDI trial will receive CGM, and evaluations will be performed on sustained glycaemic control effects, hypoglycaemia, glycaemic variability, quality of life, fear of hypoglycaemia, treatment satisfaction, physical activity, and safety.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02465411
Study type Interventional
Source Vastra Gotaland Region
Contact
Status Completed
Phase N/A
Start date June 2015
Completion date May 31, 2017
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT01508065 - Measuring and Monitoring Blood Glucose Levels Utilizing Non-invasive Blood Glucose Monitoring Device
Completed NCT01788033 - Effects of XOMA 052 on Insulin Production in Type 1 Diabetes Phase 2
Active, not recruiting NCT01271517 - Basal Analog Study - Comparison of Lantus or Levemir With NPH Insulin From T1DM Diagnosis Phase 4
Recruiting NCT01800734 - Mixed Meal Test in Type 1 Diabetes: Optimization of Artificial Pancreas-Pilot Study Phase 4
Recruiting NCT06088615 - Feasibility of Non-invasive Glucose Monitoring by Using Photothermal Deflectometry
Completed NCT02127047 - Effects of Exercise and Inhibition of Dipeptidyl Peptidase-4 on Insulin Secretion in Subjects With Type 1 Diabetes Phase 2
Completed NCT01689090 - Diameter Changes of Retinal Vessels During Hypoxia N/A
Completed NCT00006505 - Solitary Islet Transplantation for Type 1 Diabetes Mellitus Using Steroid Sparing Immunosuppression Phase 2
Not yet recruiting NCT06217302 - Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease Phase 3
Recruiting NCT02750111 - Continuous Glucose Monitoring During Intecorse in Young Adults With Type 1 Diabetes N/A
Recruiting NCT02545062 - MoCa Test for the Early Detection of Mild Cognitive Impairment During Annual Assessment of Young Adults With Diabetes and in a Control Group Without Diabetes N/A
Completed NCT02146651 - A Double-blinded, Randomised, Four-period Crossover Euglycemic Clamp Trial Investigating the Dose-response and Dose-exposure Relationship of BioChaperone Insulin Lispro in Three Different Doses in Subjects With Type 1 Diabetes Phase 2
Completed NCT02538120 - Assessment of the Neurovascular Microcirculatory Response in Diabetes Type 1 Patients N/A
Completed NCT02403375 - Comparing Continuous Subcutaneous Insulin Infusion With Multiple Daily Injections to Reach HbA1c Targets in Children and Adolescents With Type 1 Diabetes N/A
Terminated NCT00896610 - Natural History of Autoimmune Diabetes and Its Complications
Terminated NCT02701257 - The iLet Introduction Study: A Feasibility Study of the iLet, a Fully Integrated Bihormonal Bionic Pancreas N/A
Completed NCT02094534 - A Prospective, Randomized, Double-blind, Placebo Controlled Study to Assess the Impact of ORMD-0801 (Insulin Capsules) on the Exogenous Insulin Requirements of Type 1 Diabetics Phase 2
Completed NCT01334151 - Pharmacokinetic and Pharmacodynamic Properties of BIOD-105 and BIOD-107 Compared to Humalog® in Subjects With Type 1 Diabetes Phase 1
Active, not recruiting NCT02624804 - A Pilot Study of the Therapeutic Potential of Stem Cell Educator Therapy in Type 1 Diabetes Phase 1
Completed NCT02157155 - A Study of Intracellular Signaling in Muscle and Fat Cells During Ketosis N/A